Table 2.

Clinical Outcomes by Treatment Arm

Clinical Outcome	Control Group (doxorubicin and cyclophosphamide, then paclitaxel) (n = 2,018)	Trastuzumab Group (doxorubicin and cyclophosphamide, then paclitaxel and trastuzumab) (n = 2,028)
First documented disease event	680	473
Locoregional recurrence	119	82
Distant recurrence	387	228
Local and distant recurrence	29	13
Contralateral breast cancer	40	46
Other second primary cancer	74	66
Death without progressive disease, second primary, or contralateral breast disease	31	38
All deaths	418	286
Breast cancer	341	210
Second primary cancer
Solid tumor	15	15
Hematologic malignancy*	7	2
Cardiac conditions
Congestive heart failure	2	3
Cardiac arrest	1	3
Cardiomyopathy	0	1
Myocardial infarction	0	1
Unspecified cardiac condition	0	1
Sepsis/septicemia	8	1
Other causes	21	14
Unknown cause	23†	35‡

^*One case of myelodysplastic syndrome.

^†Fourteen of these 23 patients had a prior breast recurrence or second primary cancer disease.

^‡Sixteen of these 35 patients had a prior breast recurrence or second primary cancer disease.